Lupin launches generic Myfortic
Lupin is introducing its generic of Novartis' Myfortic (mycophenolic acid) delayed-release tablets. Lupin's partner, Concord had previously received Food and Drug Administration approval for the product.
The product is indicated for prophylaxis of organ rejection in adult patients receiving kidney transplants and in pediatric patients at least 5 years of age and older who are at least 6 months post kidney transplant. Lupin's generic will be available in 180- and 360-mg dosage strengths.
Mycophenolic acid delayed-release tablets had a market value of roughly $156 million, according to IQVIA date from February.